Skip to main content
OpenTrials
Completed

NCT Number: NCT02162420

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 0 - 70 years
  • Acceptable hematopoeitic stem cell donor
  • Dyskeratosis Congenita (DC) with evidence of BM failure defined as:
  • requirement for red blood cell and/or platelet transfusions or
  • requirement for G-CSF or GM-CSF or erythropoietin or
  • refractory cytopenias having one of the following three
  • platelets <50,000/uL or transfusion dependent
  • absolute neutrophil count <500/uL without hematopoietic growth factor support
  • hemoglobin <9g/uL or transfusion dependent
  • Diagnosis of DC with a triad of mucocutaneous features:
  • oral leukoplakia
  • nail dystrophy
  • abnormal reticular skin hyperpigmentation, or
  • Diagnosis of DC with one of the following:
  • short telomeres (under a research study)
  • mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1)
  • mutation in shelterin complex (TINF2)
  • mutation in telomere-capping complex (CTC1)
  • Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:
  • Refractory cytopenia defined by bone marrow cellularity <50% (with < 30% residual hematopoietic cells)
  • Diagnosis of SAA with refractory cytopenias having one of the following three:
  • platelets <20,000/uL or transfusion dependent
  • absolute neutrophil count <500/uL without hematopoietic growth factor support
  • absolute reticulocyte count <20,000/uL
  • Severe Aplastic Anemia (SAA) requiring a 2nd transplant
  • Graft failure as defined by blood/marrow chimerism of < 5%
  • Early myelodysplastic features
  • With or without clonal cytogenetic abnormalities
  • Adequate organ function defined as:
  • cardiac: left ventricular ejection fraction ≥ 35% with no evidence of decompensated heart failure
  • pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement
  • renal: Glomerular filtration rate (GFR) ≥30% predicted
  • Voluntary written consent

Exclusion criteria

  • Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
  • Pregnant or lactating
  • Uncontrolled infection
  • Prior radiation therapy (applies to SAA patients only)
  • Diagnosis of Fanconi anemia based on DEB
  • Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with >30% blasts

Treatment and study plan

Alemtuzumab

Drug

Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.

Fludarabine

Drug

Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.

Other names: Fludara

Cyclophosphamide

Drug

Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.

Total Body Irradiation

Radiation

TBI 200 cGy as a single fraction on day -1 from transplant.

Other names: TBI

Stem cell transplant

Biological

Stem cell transplant on day 0.

Other names: HSCT

anti-thymocyte globulin

Drug

ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.

Other names: Rabbit ATG

Primary outcomes

  1. Incidence of Neutrophil Engraftment

    Time frame: Day 42

    Incidence of neutrophil engraftment by day 42.

  2. Incidence of Platelet Engraftment

    Time frame: 1 year

    Incidence of platelet engraftment at 1 year

Secondary outcomes

  1. Incidence of Regimen Related Mortality

    Time frame: Day 100

    Incidence of regimen related mortality by day 100.

  2. Incidence of Acute Graft-versus-host Disease

    Time frame: Day 100

    Incidence of acute graft-versus-host disease by day 100.

  3. Incidence of Chronic Graft-versus-host Disease

    Time frame: 6 Months

    Incidence of chronic graft-versus-host disease by 6 months

  4. Incidence of Chronic Graft-versus-host Disease

    Time frame: 1 Year

    Incidence of chronic graft-versus-host disease by 1 year

  5. Incidence of Secondary Malignancies

    Time frame: 1 Year

    Incidence of secondary malingancies

Sponsors and collaborators

Lead sponsor

Masonic Cancer Center, University of Minnesota

Other

Registry information

Important dates

Study start
2015
Primary completion
2024
Study completion
2025
First posted
Jun 12, 2014
Registry last updated
May 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.